Dextran
Blood Substitutes and Plasma Protein Fractions
Sold as LMD 10% IN DEXTROSE 5% · LMD 10% IN 0.9% SODIUM…
- Drug class
- Blood Substitutes and Plasma Protein Fractions
- Availability
- Over-the-counter
- Routes
- Ophthalmic, Intravenous
- Markets covered
- 2
- Products on record
- 4
- FDA reports (12 mo)
- 137
Overview
Dextran is an active pharmaceutical ingredient in the Blood Substitutes and Plasma Protein Fractions group (B05AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 2 | April 29, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
USUnited States· FDA
2 products
Uses
Uses • relieves redness of the eye due to minor eye irritations • as a lubricant to prevent further irritation or to relieve dryness of the eye
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Dextran. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 011473a8-26d5-46… · revised April 29, 2026 [PDF]
- [2]Health Canada (DPD) · 00224227 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.